Approved Hospital Formulary
Add Formweb to your mobile device
Approved Hospital Formulary
Search results for:
rolapitant
rolapitant
- Restricted Varubi IV --> restricted to oncology for CINV and no sub orders.
- Restricted Anti-Neoplastic Formulary
- Non-formulary
- Therapeutic Interchange
Last updated: Jun. 27, 2018
Varubi tablet has no automatic interchange. Physician must be contact for alternative therapy.
Varubi infusion is restricted to oncology for CINV and no substitution orders.
Varubi has an automatic interchange to Cinvanti IV:
Varubi IV 166.5 mg = Cinvanti IV 130 mg
See dosing guidelines below. Note the variation between dexamethasone dosing in HEC or MEC with Varubi IV, Emend IV, Cinvanti IV. For 5-HT3, both Varubi IV and Emend IV package inserts reccommend following the 5-HT3 receptor antagonists guidelines for administration/dosing.
If no substitution written, follow guideliness below.
Administer intravenously within 2 hours prior to initiation of chemotherapy
Injectable emulsion: infuse 166.5 mg over 30 minutes
Administer intravenously within 2 hours prior to initiation of chemotherapy
Injectable emulsion: infuse 166.5 mg over 30 minutes
If therapeutic interchange is appropriate, follow guideliness below for Cinvanti dosing.
130 mg IVP over 2 min approximately 30 minutes before chemo
*Refer to the package insert for appropriate dosing following initial day of therapy.
130 mg IVP over 2 min approximately 30 minutes before chemo
* *Refer to the package insert for appropriate dosing following initial day of therapy.
Reviewed: 23 Jan 2018 (Tablet and IV), and 27 Feb 2018 (Interchange)